Generic Drug Tariff Scare Sinks Pharma Stocks: Nifty Index Falls Amid Trump's 100% Import Tariff Threat

Generic Drug Tariff Scare Sinks Pharma Stocks: Nifty Index Falls Amid Trump's 100% Import Tariff Threat​

Pharmaceutical Sector Reels as Trump’s Proposed Tariffs Send Shockwaves​

Shares across the Indian pharmaceutical sector experienced a downturn on Wednesday following statements made by US President Donald Trump. The concerns stemmed from his proposal that generic drugs imported into the United States would face steep tariffs, starting at 100% in August 2028 and doubling in subsequent years. This announcement immediately spooked investors who heavily rely on international trade streams.

The Nifty Pharma index registered a decline of 1.3% by market close. Simultaneously, the broader benchmark Nifty 50 also dipped, falling by 0.8%. Multiple companies within the sector saw marked losses, underscoring the immediate apprehension caused by the tariff threat.

Key Stock Performance in Response to Tariff Threat​

Lupin emerged as one of the biggest laggards, with shares falling by 4.3%. Other heavily affected stocks included Piramal Pharma and Ajanta Pharma, which declined between 2.5% and 4.2%. Aurobindo Pharma, Alembic Pharmaceuticals, and Granules (India) also saw significant declines in response to the regulatory news.

The news has a particularly negative implication for Indian pharma companies. Arijit Malakar, an equity research analyst at Ashika Stock Broking, noted that this is a challenging development for Indian drug manufacturers. He stressed that many of these firms still manufacture their medicines within India, even if they possess US facilities.

Expert Analysis on the Impact of 100% Tariffs​

The market is currently processing the potential magnitude of this tariff imposition. Malakar suggested that expanding manufacturing capacity in the US would inevitably lead to higher production costs. He added that a substantial portion of these increased costs are likely to be passed directly onto customers.

However, not all analysts share an immediate negative outlook. Prathamesh Masdekar, a research analyst at StoxBox, maintained a measured perspective. He commented that the proposed tariff is still in a preliminary stage and anticipates further negotiations, given India's crucial role as a supplier of affordable generic medicines to the US market.

Pharma’s Historical Performance vs Benchmark​

Despite the current downturn, the pharmaceutical sector has been performing robustly when compared against the Nifty 50 over recent periods. The Nifty Pharma index has shown strong growth, registering an increase of 13.3% so far in 2026. Conversely, the Nifty 50 recorded a decline of 8.2% within the same period.

Maitri Sheth, an analyst from Choice Institutional Equities, provided insight into the proposal's scope. She noted that this specific plan introduces generics, which represent one of the primary revenue streams for Indian pharmaceutical companies in the US market, squarely into the focus of potential tariffs for the first time. Investors are now urged to evaluate domestic-focused firms as a defensive strategy.